OTC Markets OTCPK - Delayed Quote USD

GSK plc (GLAXF)

16.86

0.00

(0.00%)

At close: January 10 at 3:00:00 PM EST

Why Is GSK plc (NYSE:GSK) Among the Best FTSE Dividend Stocks to Buy Now?

We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025, with GDP rising 1.2%. That is slightly […]

Insider Monkey 6 days ago

GSK

^FTSE
GSK’s Nucala Gains Approval in China for CRSwNP

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval marks the third indication for mepolizumab in China and offers patients a non-surgical treatment alternative to systemic corticosteroids and surgery. The approval is based on successful trials demonstrating its

TipRanks 8 days ago

GLAXF
0.00%
GSK
GSK's Sinus Disease Drug Secures Approval In China

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. The FDA approved Nucala for the same indication in July 2021. This is the third indication for mepolizumab in China for an IL-5 mediated condition. It is estim

Benzinga 9 days ago

GSK
Can GSK plc (LON:GSK) Maintain Its Strong Returns?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. 13 days ago

GLAXF
0.00%
GSK
GSK announces CHMP of the EMA recommended expanding approval of Jemperli

GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy for first-line treatment of all adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This would include patients with mismatch repair proficient /microsatellite stable tumours, who represent 70-75% of patients diagnosed with endometrial cance

TipRanks 26 days ago

GLAXF
0.00%
GSK
GSK announces FDA granted BTD for Jemperli

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for Jemperli for the treatment of patients with locally advanced mismatch repair deficient/microsatellite instability-high, MSI-H, rectal cancer. The Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to treat a serious condition and where preliminary clinical evidence may indicate substantial improvement over currently availa

TipRanks 26 days ago

GLAXF
0.00%
GSK
GSK’s lung cancer therapy gains EMA PRIME designation

The EMA's decision is based on the early clinical outcomes from the ARTEMIS-001 study.

Pharmaceutical Technology 26 days ago

GSK
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

On Monday, GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial. The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) in combination with bortezomib plus dexamethasone (DVd) as a second line or later treatment for relapsed or refractory multiple myeloma. These data were fea

Benzinga last month

GSK
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

PHILADELPHIA, December 09, 2024--Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

Business Wire last month

GLAXF
0.00%
GSK
Investors shift to US funds and tech in November amid lower interest rates

Investors put a record £3.1bn into British equity funds last month.

Yahoo Finance UK last month

^FTSE

0P0000P2IY.L

0P0000P2IZ.L
GSK (LON:GSK) investors are sitting on a loss of 3.4% if they invested five years ago

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

Simply Wall St. last month

GLAXF
0.00%
GSK
GSK gains approval in Japan for extended indication of RSV vaccine

The decision is based on Phase III trial outcomes.

Pharmaceutical Technology last month

GSK
GSK announces Japan’s MHLW approved application to extend indication of Arexvy

GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include adults aged 50-59 at increased risk. Since September 2023, GSK’s RSV vaccine has been approved in Japan for adults aged 60 and over for the prevention of RSV disease. Tony Wood, Chief Scientific Officer at GSK, said: “This approval reflects our ambition to protect people at increased risk from the seve

TipRanks last month

GLAXF
0.00%
GSK
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo. Also Read: GSK Raises Prospects For Withdrawn Blood

Benzinga last month

GSK
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the “Company”) is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. “We are thrilled to welcome Dr. Mehmud to our leadership team,” stated Dr. Raza Bokhari, Exec. Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base

GlobeNewswire last month

GLAXF
0.00%
GSK
How analysts are reacting to RFK Jr. as Trump's HHS pick

President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the "Disinformation Dozen" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

Yahoo Finance Video last month

MRNA

SNY

SNYNF
0.00%
Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk

↘️ Applied Materials (AMAT): Shares fell 8% after the semiconductor-equipment company posted a weaker-than-expected sales outlook. ↘️ Alibaba (BABA): The Chinese e-commerce company posted better-than-expected quarterly earnings, but disappointing revenue.

The Wall Street Journal last month

SNY

SNYNF
0.00%
AZN
Trump’s RFK Jr. Pick Weighs on Vaccine Makers

Kennedy, a vaccine skeptic, has promised sweeping changes to food and drug regulation and government-funded scientific research.

The Wall Street Journal last month

AZN

AZNCF
0.00%
BNTX
Trump looks to end EV credit, vaccine stocks fall on RFK JR. pick

Electric vehicle stocks Tesla (TSLA) and Rivian (RIVN) are in focus amid reports that President-elect Donald Trump plans to end the federal tax credit for electric vehicle purchases. The $7500 subsidy has been a key incentive driving consumer adoption of EVs in the US, and its removal could make these vehicles less affordable. Additionally, vaccine maker stocks like Moderna (MRNA) and Pfizer (PFE) are falling after Trump named Robert F. Kennedy Jr. as Secretary of Health and Human Services. Kennedy Jr. has been openly skeptical of vaccines. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith

Yahoo Finance Video last month

RIVN

BNTX

GLAXF
0.00%
Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.

President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the US Health and Human Services Department. Vaccine stocks slid on the news.

Yahoo Finance last month

SNY

SNYNF
0.00%
AZN

Performance Overview

Return	GLAXF	FTSE 100
YTD	+0.96%	+1.57%
1-Year	-10.57%	+7.35%
3-Year	-9.23%	+10.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GSK plc (GLAXF)

Why Is GSK plc (NYSE:GSK) Among the Best FTSE Dividend Stocks to Buy Now?

GSK’s Nucala Gains Approval in China for CRSwNP

GSK's Sinus Disease Drug Secures Approval In China

Can GSK plc (LON:GSK) Maintain Its Strong Returns?

GSK announces CHMP of the EMA recommended expanding approval of Jemperli

GSK announces FDA granted BTD for Jemperli

GSK’s lung cancer therapy gains EMA PRIME designation

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

Investors shift to US funds and tech in November amid lower interest rates

GSK (LON:GSK) investors are sitting on a loss of 3.4% if they invested five years ago

GSK gains approval in Japan for extended indication of RSV vaccine

GSK announces Japan’s MHLW approved application to extend indication of Arexvy

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

How analysts are reacting to RFK Jr. as Trump's HHS pick

Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk

Trump’s RFK Jr. Pick Weighs on Vaccine Makers

Trump looks to end EV credit, vaccine stocks fall on RFK JR. pick

Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.

Performance Overview